Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF) (2010 - 2026)

Jazz Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 12.5% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $40.3 million (up 13.62% YoY), and the FY2025 full-year result was $41.6 million, up 27.12% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $9.1 million, down from $9.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $11.9 million in Q2 2025, with the low at $7.3 million in Q4 2022.
• Average Depreciation & Amortization (CF) over 5 years is $8.5 million, with a median of $7.7 million recorded in 2022.
• Year-over-year, Depreciation & Amortization (CF) jumped 59.38% in 2022 and fell 12.5% in 2026.
• Tracing JAZZ's Depreciation & Amortization (CF) over 5 years: stood at $7.3 million in 2022, then rose by 4.14% to $7.6 million in 2023, then gained by 24.4% to $9.5 million in 2024, then dropped by 0.91% to $9.4 million in 2025, then decreased by 3.47% to $9.1 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $9.1 million (Q1 2026), $9.4 million (Q4 2025), and $9.9 million (Q3 2025), per Business Quant data.

Peer Comparison